194 related articles for article (PubMed ID: 17039268)
1. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
Hernández-Vargas H; Rodríguez-Pinilla SM; Julián-Tendero M; Sánchez-Rovira P; Cuevas C; Antón A; Ríos MJ; Palacios J; Moreno-Bueno G
Breast Cancer Res Treat; 2007 Apr; 102(2):157-72. PubMed ID: 17039268
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
4. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Karelia DN; Kim S; K Pandey M; Plano D; Amin S; Lu J; Sharma AK
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067020
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Yu C; Chen S; Guo Y; Sun C
Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
[No Abstract] [Full Text] [Related]
6. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
7. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
[TBL] [Abstract][Full Text] [Related]
9. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
11. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
[TBL] [Abstract][Full Text] [Related]
13. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
Zhang W; Chen H; Liu DL; Li H; Luo J; Zhang JH; Li Y; Chen KJ; Tong HF; Lin SZ
Int J Oncol; 2013 Apr; 42(4):1189-96. PubMed ID: 23440366
[TBL] [Abstract][Full Text] [Related]
14. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
16. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
[TBL] [Abstract][Full Text] [Related]
17. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
